This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
North American Prodromal Synucleinopathy Consortium Stage 2
-
University of California Los Angeles, Los Angeles, California, United States, 90095
Stanford University, Redwood City, California, United States, 94063
Emory University, Atlanta, Georgia, United States, 30322
Massachusetts General Hospital, Boston, Massachusetts, United States, 02145
University of Minnesota, Minneapolis, Minnesota, United States, 55414
Mayo Clinic Rochester, Rochester, Minnesota, United States, 55905
Washington University School of Medicine, Saint Louis, Missouri, United States, 63110
Oregon Health Sciences University, Portland, Oregon, United States, 97239
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
Yes
Washington University School of Medicine,
Yo-El Ju, MD, MCSI, PRINCIPAL_INVESTIGATOR, Washington University School of Medicine
Brad Boeve, MD, PRINCIPAL_INVESTIGATOR, Mayo Clinic
Ron Postuma, MD, PRINCIPAL_INVESTIGATOR, McGill University
2025-05-01